{"id":4459,"date":"2020-01-31T10:39:05","date_gmt":"2020-01-31T10:39:05","guid":{"rendered":"https:\/\/www.maatpharma.com\/?p=4459"},"modified":"2026-01-22T18:24:35","modified_gmt":"2026-01-22T16:24:35","slug":"maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics","status":"publish","type":"post","link":"https:\/\/www.maatpharma.com\/fr\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics\/","title":{"rendered":"MaaT Pharma Announces \u20ac18 Million  Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics"},"content":{"rendered":"<p><strong>Lyon, France, February 5, 2020 \u2013<\/strong> <a href=\"https:\/\/www.maatpharma.com\/fr\/\">MaaT Pharma<\/a> announced today an \u20ac18 million Series B financing round including a microbiome-focused US investor, SymBiosis, LLC, and support from its existing investors Seventure Partners, Cr\u00e9dit Mutuel Innovation, and Biocodex. The funding will enable the continued clinical development of the company\u2019s current pipeline, as well as the expansion into additional oncological indications where restoring a functional microbiome could provide significant therapeutic benefit when combined with other cancer treatments such as immune checkpoint inhibitors.\u201cWe are excited to have added a US-based investor to our\u00a0 syndicate based on the strategic importance of the US market for our future development. I would like to thank our existing investors and our network of scientific advisors for their continued support as we enter into this next development phase for the company,\u201d said Herv\u00e9 Affagard, co-founder and CEO of MaaT Pharma. \u201cA growing body of evidence suggests that a functional microbiome can improve cancer outcomes, and we look forward to continue building on our initial proof of concept by going beyond hematological malignancies into solid tumors.\u201dThe proceeds will be used to complete the ongoing HERACLES Phase II clinical trial (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03359980\">NCT03359980<\/a>) of MaaT\u2019s lead compound, MaaT013, in patients that developed steroid-refractory, gastrointestinal-predominant, acute Graft-versus-Host-Disease (SR aGvHD) following allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). In addition, the company will accelerate the development of a capsule formulation of MaaT013, MaaT033, which will ease administration and facilitate the expansion of the company\u2019s pipeline into new oncological indications, including the initiation of a Phase 1b clinical trial with MaaT033. <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/sites\/myncbi\/jacob.verghese.1\/collections\/59233803\/public\/\">Recent studies<\/a> demonstrated that restoring a balanced microbiome can significantly improve the clinical outcomes of checkpoint inhibitors, and MaaT Pharma will investigate this potential in a combination trial in solid tumors. Preliminary data from the safety and dose-finding Phase 1b trial of MaaT033 is expected in H2 2020.MaaT Pharma\u2019s product candidates are based on the company\u2019s proprietary MaaT Microbiome Restoration Biotherapeutics (MMRB) platform. MaaT Pharma\u2019s lead product candidate, MaaT013, is an enema formulation characterized by a high consistent richness of microbial species, whose specific bacteria are protected thanks to a proprietary formulation, derived from pooling the full intestinal ecosystems of stringently vetted, healthy donors. The product is manufactured at MaaT\u2019s centralized European cGMP production facility. Apart from the ongoing HERACLES Phase II trial, from which results are expected in 2020, MaaT has provided MaaT013 to a compassionate use program for patients who had failed to respond to previous treatments for SR aGvHD. In total, over 50 patients with severe hematological malignancies have been treated with the company\u2019s product candidate. The data collected up to date demonstrate that reintroduction of a full-ecosystem microbiota is well tolerated in these patients and provides initial signs of therapeutic benefit. Initial results from the company\u2019s compassionate use program were <a href=\"https:\/\/www.maatpharma.com\/fr\/ash-2019\/\">presented at the 2019 ASH conference<\/a> in Orlando, Florida.<\/p>\n<h3><em>About MaaT Pharma<\/em><\/h3>\n<p>MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating a range of cancers and Graft-versus-Host-Disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into improving outcomes of immunotherapy in solid tumors, we have built a powerful discovery and analysis platform, GutPrint\u00ae, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our biotherapeutics are produced under the strictest cGMP manufacturing and quality control process to safely deliver the full diversity and functionality of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead the integration of microbiome treatment into clinical practice.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lyon, France, February 5, 2020 \u2013 MaaT Pharma announced today an \u20ac18 million Series B financing round including a microbiome-focused US investor, SymBiosis, LLC, and support from its existing investors Seventure Partners, Cr\u00e9dit Mutuel Innovation, and Biocodex. The funding will enable the continued clinical development of the company\u2019s current pipeline, as well as the expansion into additional oncological indications where restoring a functional microbiome could provide significant therapeutic benefit when combined with other cancer treatments such as immune checkpoint inhibitors.\u201cWe are excited to have added a US-based investor to our\u00a0 syndicate based on the strategic importance of the US market for our future development. I would like to thank our existing investors and our network of scientific advisors for their continued support as we enter into this next development phase for the company,\u201d said Herv\u00e9 Affagard, co-founder and CEO of MaaT Pharma. \u201cA growing body of evidence suggests that a functional microbiome can improve cancer outcomes, and we look forward to continue building on our initial proof of concept by going beyond hematological malignancies into solid tumors.\u201dThe proceeds will be used to complete the ongoing HERACLES Phase II clinical trial (NCT03359980) of MaaT\u2019s lead compound, MaaT013, in patients that developed steroid-refractory, gastrointestinal-predominant, acute Graft-versus-Host-Disease (SR aGvHD) following allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). In addition, the company will accelerate the development of a capsule formulation of MaaT013, MaaT033, which will ease administration and facilitate the expansion of the company\u2019s pipeline into new oncological indications, including the initiation of a Phase 1b clinical trial with MaaT033. Recent studies demonstrated that restoring a balanced microbiome can significantly improve the clinical outcomes of checkpoint inhibitors, and MaaT Pharma will investigate this potential in a combination trial in solid tumors. Preliminary data from the safety and dose-finding Phase 1b trial of MaaT033 is expected in H2 2020.MaaT Pharma\u2019s product candidates are based on the company\u2019s proprietary MaaT Microbiome Restoration Biotherapeutics (MMRB) platform. MaaT Pharma\u2019s lead product candidate, MaaT013, is an enema formulation characterized by a high consistent richness of microbial species, whose specific bacteria are protected thanks to a proprietary formulation, derived from pooling the full intestinal ecosystems of stringently vetted, healthy donors. The product is manufactured at MaaT\u2019s centralized European cGMP production facility. Apart from the ongoing HERACLES Phase II trial, from which results are expected in 2020, MaaT has provided MaaT013 to a compassionate use program for patients who had failed to respond to previous treatments for SR aGvHD. In total, over 50 patients with severe hematological malignancies have been treated with the company\u2019s product candidate. The data collected up to date demonstrate that reintroduction of a full-ecosystem microbiota is well tolerated in these patients and provides initial signs of therapeutic benefit. Initial results from the company\u2019s compassionate use program were presented at the 2019 ASH conference in Orlando, Florida. About MaaT Pharma MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating a range of cancers and Graft-versus-Host-Disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into improving outcomes of immunotherapy in solid tumors, we have built a powerful discovery and analysis platform, GutPrint\u00ae, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our biotherapeutics are produced under the strictest cGMP manufacturing and quality control process to safely deliver the full diversity and functionality of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead the integration of microbiome treatment into clinical practice.<\/p>\n","protected":false},"author":2,"featured_media":4333,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[21],"tags":[],"category_press":[],"year_press":[50],"class_list":["post-4459","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communiques-de-presse-fr","year_press-50"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MaaT Pharma Announces \u20ac18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics - MaaT Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.maatpharma.com\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaaT Pharma Announces \u20ac18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics - MaaT Pharma\" \/>\n<meta property=\"og:description\" content=\"Lyon, France, February 5, 2020 \u2013 MaaT Pharma announced today an \u20ac18 million Series B financing round including a microbiome-focused US investor, SymBiosis, LLC, and support from its existing investors Seventure Partners, Cr\u00e9dit Mutuel Innovation, and Biocodex. The funding will enable the continued clinical development of the company\u2019s current pipeline, as well as the expansion into additional oncological indications where restoring a functional microbiome could provide significant therapeutic benefit when combined with other cancer treatments such as immune checkpoint inhibitors.\u201cWe are excited to have added a US-based investor to our\u00a0 syndicate based on the strategic importance of the US market for our future development. I would like to thank our existing investors and our network of scientific advisors for their continued support as we enter into this next development phase for the company,\u201d said Herv\u00e9 Affagard, co-founder and CEO of MaaT Pharma. \u201cA growing body of evidence suggests that a functional microbiome can improve cancer outcomes, and we look forward to continue building on our initial proof of concept by going beyond hematological malignancies into solid tumors.\u201dThe proceeds will be used to complete the ongoing HERACLES Phase II clinical trial (NCT03359980) of MaaT\u2019s lead compound, MaaT013, in patients that developed steroid-refractory, gastrointestinal-predominant, acute Graft-versus-Host-Disease (SR aGvHD) following allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). In addition, the company will accelerate the development of a capsule formulation of MaaT013, MaaT033, which will ease administration and facilitate the expansion of the company\u2019s pipeline into new oncological indications, including the initiation of a Phase 1b clinical trial with MaaT033. Recent studies demonstrated that restoring a balanced microbiome can significantly improve the clinical outcomes of checkpoint inhibitors, and MaaT Pharma will investigate this potential in a combination trial in solid tumors. Preliminary data from the safety and dose-finding Phase 1b trial of MaaT033 is expected in H2 2020.MaaT Pharma\u2019s product candidates are based on the company\u2019s proprietary MaaT Microbiome Restoration Biotherapeutics (MMRB) platform. MaaT Pharma\u2019s lead product candidate, MaaT013, is an enema formulation characterized by a high consistent richness of microbial species, whose specific bacteria are protected thanks to a proprietary formulation, derived from pooling the full intestinal ecosystems of stringently vetted, healthy donors. The product is manufactured at MaaT\u2019s centralized European cGMP production facility. Apart from the ongoing HERACLES Phase II trial, from which results are expected in 2020, MaaT has provided MaaT013 to a compassionate use program for patients who had failed to respond to previous treatments for SR aGvHD. In total, over 50 patients with severe hematological malignancies have been treated with the company\u2019s product candidate. The data collected up to date demonstrate that reintroduction of a full-ecosystem microbiota is well tolerated in these patients and provides initial signs of therapeutic benefit. Initial results from the company\u2019s compassionate use program were presented at the 2019 ASH conference in Orlando, Florida. About MaaT Pharma MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating a range of cancers and Graft-versus-Host-Disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into improving outcomes of immunotherapy in solid tumors, we have built a powerful discovery and analysis platform, GutPrint\u00ae, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our biotherapeutics are produced under the strictest cGMP manufacturing and quality control process to safely deliver the full diversity and functionality of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead the integration of microbiome treatment into clinical practice.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.maatpharma.com\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\/\" \/>\n<meta property=\"og:site_name\" content=\"MaaT Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2020-01-31T10:39:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T16:24:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"MaaT Pharma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"MaaT Pharma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\\\/\"},\"author\":{\"name\":\"MaaT Pharma\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"MaaT Pharma Announces \u20ac18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics\",\"datePublished\":\"2020-01-31T10:39:05+00:00\",\"dateModified\":\"2026-01-22T16:24:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\\\/\"},\"wordCount\":632,\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\\\/\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\\\/\",\"name\":\"MaaT Pharma Announces \u20ac18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics - MaaT Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"datePublished\":\"2020-01-31T10:39:05+00:00\",\"dateModified\":\"2026-01-22T16:24:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"contentUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma Announces \u20ac18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"name\":\"MaaT Pharma\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.maatpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"MaaT Pharma\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaaT Pharma Announces \u20ac18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics - MaaT Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.maatpharma.com\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\/","og_locale":"fr_FR","og_type":"article","og_title":"MaaT Pharma Announces \u20ac18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics - MaaT Pharma","og_description":"Lyon, France, February 5, 2020 \u2013 MaaT Pharma announced today an \u20ac18 million Series B financing round including a microbiome-focused US investor, SymBiosis, LLC, and support from its existing investors Seventure Partners, Cr\u00e9dit Mutuel Innovation, and Biocodex. The funding will enable the continued clinical development of the company\u2019s current pipeline, as well as the expansion into additional oncological indications where restoring a functional microbiome could provide significant therapeutic benefit when combined with other cancer treatments such as immune checkpoint inhibitors.\u201cWe are excited to have added a US-based investor to our\u00a0 syndicate based on the strategic importance of the US market for our future development. I would like to thank our existing investors and our network of scientific advisors for their continued support as we enter into this next development phase for the company,\u201d said Herv\u00e9 Affagard, co-founder and CEO of MaaT Pharma. \u201cA growing body of evidence suggests that a functional microbiome can improve cancer outcomes, and we look forward to continue building on our initial proof of concept by going beyond hematological malignancies into solid tumors.\u201dThe proceeds will be used to complete the ongoing HERACLES Phase II clinical trial (NCT03359980) of MaaT\u2019s lead compound, MaaT013, in patients that developed steroid-refractory, gastrointestinal-predominant, acute Graft-versus-Host-Disease (SR aGvHD) following allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). In addition, the company will accelerate the development of a capsule formulation of MaaT013, MaaT033, which will ease administration and facilitate the expansion of the company\u2019s pipeline into new oncological indications, including the initiation of a Phase 1b clinical trial with MaaT033. Recent studies demonstrated that restoring a balanced microbiome can significantly improve the clinical outcomes of checkpoint inhibitors, and MaaT Pharma will investigate this potential in a combination trial in solid tumors. Preliminary data from the safety and dose-finding Phase 1b trial of MaaT033 is expected in H2 2020.MaaT Pharma\u2019s product candidates are based on the company\u2019s proprietary MaaT Microbiome Restoration Biotherapeutics (MMRB) platform. MaaT Pharma\u2019s lead product candidate, MaaT013, is an enema formulation characterized by a high consistent richness of microbial species, whose specific bacteria are protected thanks to a proprietary formulation, derived from pooling the full intestinal ecosystems of stringently vetted, healthy donors. The product is manufactured at MaaT\u2019s centralized European cGMP production facility. Apart from the ongoing HERACLES Phase II trial, from which results are expected in 2020, MaaT has provided MaaT013 to a compassionate use program for patients who had failed to respond to previous treatments for SR aGvHD. In total, over 50 patients with severe hematological malignancies have been treated with the company\u2019s product candidate. The data collected up to date demonstrate that reintroduction of a full-ecosystem microbiota is well tolerated in these patients and provides initial signs of therapeutic benefit. Initial results from the company\u2019s compassionate use program were presented at the 2019 ASH conference in Orlando, Florida. About MaaT Pharma MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating a range of cancers and Graft-versus-Host-Disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into improving outcomes of immunotherapy in solid tumors, we have built a powerful discovery and analysis platform, GutPrint\u00ae, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our biotherapeutics are produced under the strictest cGMP manufacturing and quality control process to safely deliver the full diversity and functionality of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead the integration of microbiome treatment into clinical practice.","og_url":"https:\/\/www.maatpharma.com\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\/","og_site_name":"MaaT Pharma","article_published_time":"2020-01-31T10:39:05+00:00","article_modified_time":"2026-01-22T16:24:35+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","type":"image\/jpeg"}],"author":"MaaT Pharma","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"MaaT Pharma","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\/#article","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\/"},"author":{"name":"MaaT Pharma","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"MaaT Pharma Announces \u20ac18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics","datePublished":"2020-01-31T10:39:05+00:00","dateModified":"2026-01-22T16:24:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\/"},"wordCount":632,"publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"image":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\/","url":"https:\/\/www.maatpharma.com\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\/","name":"MaaT Pharma Announces \u20ac18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics - MaaT Pharma","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\/#primaryimage"},"image":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","datePublished":"2020-01-31T10:39:05+00:00","dateModified":"2026-01-22T16:24:35+00:00","breadcrumb":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.maatpharma.com\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\/#primaryimage","url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","contentUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-e18-million-series-b-financing-round-to-support-further-clinical-development-of-microbiome-biotherapeutics-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.maatpharma.com\/fr\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma Announces \u20ac18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.maatpharma.com\/#website","url":"https:\/\/www.maatpharma.com\/","name":"MaaT Pharma","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.maatpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.maatpharma.com\/#organization","name":"Maat Pharma","url":"https:\/\/www.maatpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"MaaT Pharma"}]}},"_links":{"self":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/4459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/comments?post=4459"}],"version-history":[{"count":0,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/4459\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media\/4333"}],"wp:attachment":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media?parent=4459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/categories?post=4459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/tags?post=4459"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/category_press?post=4459"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/year_press?post=4459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}